Comparative crossover trial of two intravenous doses of Granisetron (1 mg vs 3 mg) + Dexamethasone in the prevention of acute Cis-platinum-induced emesis

Anticancer Research

Volumn 18, Issue 4 B, 1998, Pages 2799-2803

  Martoni, A ^a   Piana, E ^a   Strocchi, E ^b   Angelelli, B ^a   Guaraldi, M ^a   Zamagni, C ^a   Camaggi, C M ^c   Pannuti, F ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Biostatistics and Data Management   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Acute emesis; Granisetron

Indexed keywords

CISPLATIN; DEXAMETHASONE; GRANISETRON;

ADULT; AGED; ARTICLE; BLADDER CANCER; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; VOMITING;

ADULT; AGED; ANTIEMETICS; CISPLATIN; CROSS-OVER STUDIES; DEXAMETHASONE; FEMALE; GRANISETRON; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NAUSEA; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME; VOMITING;

EID: 0031842497     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Hesketh PJ, Gandara DR. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 83: 613-6207,1991.
2. Martoni A, Angelelli B, Guaraldi M, Strocchi E, Pannuti F: An open randomized cross-over study on Granisetron vs. Ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-induced -containing regimens. Eur J Cancer 32A(1): 83-83, 1996.
3. Kamanabrou D on behalf of the Granisetron Study Group: Intravenous granisetron-establising the optimal dose. Eur J Cancer 28A (suppl. 1): S6-S11, 1992.
4. Navari RM, Kaplan HG, Gralla RJ et al: Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 12: 2204-2210, 1994.
5. Riviere A on behalf of the Granisetron Study Group. Dose finding study of granisetron in patients receiving high dose cisplatin chemotherapy. Br J Cancer 69: 967-971, 1994.
6. D'Olimpio JT, Camacho F, Chandra P et al: Antiemetic efficacy of high-dose dexamethasone versus placebo in patients receiving cisplatinum-based chemotherapy: a randomized double-blind controlled clinical trial. J Clin Oncol 3: 1133-1135, 1985.
7. Schallier D, Van BeCle S; De Greve J, Willekens A: Methyl-prednisolone as an antiemetic drug. Cancer Chemoter Pharmacol 4: 235-237, 1985.
8. Roila F, Tonato M, Basurto C: Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatinum-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical research. J Clin Oncol 5: 141-149, 1987.
9. Strum SB, McDermed JE, Liponi DF: High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatinum-induced nausea and emesis: a single-blind cross-over comparison of antiemetic efficacy. J Clin Oncol 3: 245-251, 1985.
10. Roila F, Tonato M, Cognetti F et al: Prevention of cisplatin-induced emesis: a double-blind multicentrer randomized crossover study comparing Ondasetron and ondasetron plus dexamethasone. J Clin Oncol 9: 675-678, 1991.
11. Hesketh PJ, Harvey WH, Beck T et al: A randomized double-bliind comparison of intravenous Ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 12: 596-600, 1994.
12. Joss RA, Bacchi M, Buser K et al: Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previuosly treated patients. Ann Oncol 5: 253-258, 1994.
13. Machin D, Carnpbell MJ: Statistical tables for the design of clinical trials. Blackwell Scientific Pub., Oxford, 1987.
14. Dixon WJ: BMDP Statistical Software-Rel. 7. University of California Press. Los Angeles, 1992.
15. Italian Group for Antiemetic Reserch. Ondansetron versus granisetron both combined with dexamethasone, in the prevention of cisplatinum-induced emesis. Ann Oncol 6: 805-810, 1995.